ACS 2018: Evaluation of a Predefined Active Surveillance Threshold in a Large Cohort of Men with Localized Prostate Cancer
Boston, Massachusetts (UroToday.com) Daniel J. Canter, MD evaluated the performance of the AS threshold in a contemporary cohort of men with newly diagnosed localized prostate cancer. Men with localized prostate cancer historically select active surveillance (AS) using clinicopathologic features. However, a clinical cell−cycle risk (CCR) score has been developed including both molecular [cell cycle progression (CCP)] and clinical [Cancer of the Prostate Risk Assessment (CAPRA)] features.
ACS 2018: Evaluating the Impact of African-American Ancestry Among Men with Localized Prostate Cancer Treated with Radical Prostatectomy
Boston, Massachusetts (UroToday.com) Daniel J. Canter, MD examined the effects of ancestry on clinical and molecular measures of disease aggressiveness as well as pathologic outcomes in men treated with radical prostatectomy (RP) for localized prostate cancer.